Research and Development Funding and Horizon Europe

Stewart Hosie Excerpts
Tuesday 18th April 2023

(1 year, 7 months ago)

Westminster Hall
Read Full debate Read Hansard Text Read Debate Ministerial Extracts

Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.

Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Paul Blomfield Portrait Paul Blomfield (Sheffield Central) (Lab)
- Hansard - - - Excerpts

I beg to move,

That this House has considered research and development funding and Horizon Europe.

I am pleased to serve under your chairmanship, Mr Hosie —I am trying to speak slowly enough that we might have the vote before I start my substantive comments. I am grateful to have been granted this debate to discuss the benefits of UK association with Horizon Europe, just as the Government are at an important stage of discussions with the European Commission. Research and development are clearly integral to ambition for growth and the productivity challenge that we face.

We have a special asset in the UK, in our universities. We often use the phrase “world leading” a little too casually in this place, but it certainly applies to our universities and the research they do, which helps us build our economy, creates innovative solutions to global problems and positions us internationally. Universities pay their way many times over. For every pound spent on public research funding, universities deliver an average return of £9 to the UK economy. Importantly, given the geographical spread of our universities, beyond the golden triangle and across all four nations of the country, R&D enables our universities working with business and industry to lead prosperity in towns and cities in every part of the UK. I know that from my city of Sheffield, where the University of Sheffield’s advanced manufacturing research centre is rightly held up as a model by Government—a model that would not exist had it not been for European funding.

Stewart Hosie Portrait Stewart Hosie (in the Chair)
- Hansard - -

Order. Forgive me; I was expecting to hear a bell. We will suspend the sitting for 15 minutes for the first vote and 10 minutes for any subsequent votes. I am not sure precisely how many Divisions there are, so I will see you back in 15, 25, 35 or 45 minutes.

--- Later in debate ---
On resuming—
Stewart Hosie Portrait Stewart Hosie (in the Chair)
- Hansard - -

The sitting will run until 6.8 pm. Those with very agile mental arithmetic will work out that I want to start the winding-up speeches no later than quarter to 6.

Paul Blomfield Portrait Paul Blomfield
- Hansard - - - Excerpts

It is good to see you again so soon, Mr Hosie. I think that, when we were interrupted in such an untimely way, I was talking about the AMRC in Sheffield. Its partnership with Boeing and Rolls-Royce has shown how universities and industry can work together effectively, and participation in Horizon and the earlier framework programmes was vital to its development.

It is not just big companies—for example, Footprint, which is a tool-making SME with hundreds of years of history in Sheffield, has been involved with several Horizon-funded projects, including as a lead industrial partner working with companies and researchers across Europe to develop new additive manufacturing processes for metal components for the aerospace sector. Its chairman, Christopher Jewitt, said of Horizon that

“it’s important to rub shoulders with other manufacturers in Europe…we are competing with the world”.

There is a lot at risk if we fail to associate with Horizon Europe.

Let me use another example. EU-funded research and collaboration laid the foundations for the University of Sheffield’s gene therapy innovation and manufacturing centre, which is now leveraging private investment to develop promising treatments for millions of patients with life-threatening illnesses.

--- Later in debate ---
Philip Dunne Portrait Philip Dunne (Ludlow) (Con)
- Hansard - - - Excerpts

I congratulate the hon. Gentleman on securing the debate. It is important that we talk about the significance of Horizon; I am sure that he will go on to welcome the fact that negotiations with the EU have now been reopened by the Government, and I am sure that the Minister will be able to talk to that when he sums up.

On collaboration, let me give the hon. Member one other pertinent example, which has come to my attention as a result of the Environmental Audit Committee’s work with universities, not just in the golden triangle but including the hon. Gentleman’s university in Sheffield. Imperial College was host to our 25th-anniversary celebration the other day, and the president gave me a good example of the reach that Horizon has given the UK, specifically in collaboration. He talked about the graphene core 3 project, which had 160 partner organisations across 24 countries; allowed the UK research community to compete with the US and China, which have significant infrastructure themselves; and helped to spin out Bramble Energy, an industrial company that is developing graphene. The industrial connections are important as well.

Stewart Hosie Portrait Stewart Hosie (in the Chair)
- Hansard - -

Order. I do not mind slightly extended interventions when time permits, but that was longer that some speeches I have heard.

Paul Blomfield Portrait Paul Blomfield
- Hansard - - - Excerpts

Thank you, Mr Hosie, but it was nevertheless an important intervention to hear and, given the authority of the Chair of the Environmental Audit Committee, worth noting. I thank the right hon. Gentleman for making it.

There are countless similar examples. The example that I was giving about the gene therapy innovation and manufacturing centre is similar in many ways. It is led by Professor Mimoun Azzouz, who has won several prestigious EU framework programme awards. He leads a consortium of 34 international partners from academia and business, including big pharmaceutical companies, that is progressing gene therapy approaches for industry and patients. It is part-funded by the EU and part-funded by industry. The earlier funding that he received was European Research Council funding. The next step for his project is an ERC synergy grant, which will not be open to him if we are reduced to third-country participation in Horizon. That is an important point, and there will be many similar projects.

--- Later in debate ---
None Portrait Several hon. Members rose—
- Hansard -

Stewart Hosie Portrait Stewart Hosie (in the Chair)
- Hansard - -

Order. I will start the wind-ups shortly after quarter to six. There will be five minutes for the SNP, five minutes for Labour, 10 minutes for the Minister, and a short time for the mover of the motion. If the remaining Back Benchers can take around six minutes, everything will be fantastic. I call Rachael Maskell.